A detailed history of Met Life Investment Management, LLC transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 28,266 shares of AVXL stock, worth $127,479. This represents 0.0% of its overall portfolio holdings.

Number of Shares
28,266
Holding current value
$127,479
% of portfolio
0.0%

Shares

33 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$4.55 - $6.75 $128,610 - $190,795
28,266 New
28,266 $143,000
Q2 2023

Apr 29, 2024

BUY
$7.66 - $9.5 $277,667 - $344,365
36,249 New
36,249 $294,000
Q1 2023

May 09, 2024

BUY
$8.32 - $11.75 $301,591 - $425,925
36,249 New
36,249 $311 Million
Q3 2022

May 10, 2024

BUY
$8.9 - $12.86 $22,721 - $32,831
2,553 Added 7.58%
36,249 $374,000
Q3 2022

Mar 22, 2023

BUY
$8.9 - $12.86 $22,721 - $32,831
2,553 Added 7.58%
36,249 $374,000
Q3 2022

Nov 14, 2022

BUY
$8.9 - $12.86 $22,721 - $32,831
2,553 Added 7.58%
36,249 $374,000
Q2 2022

May 10, 2024

SELL
$7.31 - $12.84 $23,530 - $41,331
-3,219 Reduced 8.72%
33,696 $337,000
Q2 2022

Jun 20, 2023

SELL
$7.31 - $12.84 $18,662 - $32,780
-2,553 Reduced 7.04%
33,696 $337,000
Q2 2022

Mar 22, 2023

SELL
$7.31 - $12.84 $23,530 - $41,331
-3,219 Reduced 8.72%
33,696 $337,000
Q2 2022

Aug 11, 2022

SELL
$7.31 - $12.84 $23,530 - $41,331
-3,219 Reduced 8.72%
33,696 $337,000
Q1 2022

May 10, 2024

BUY
$9.74 - $17.69 $359,552 - $653,026
36,915 New
36,915 $454,000
Q1 2022

Jun 20, 2023

BUY
$9.74 - $17.69 $6,486 - $11,781
666 Added 1.84%
36,915 $454,000
Q1 2022

Mar 22, 2023

BUY
$9.74 - $17.69 $132,688 - $240,990
13,623 Added 58.49%
36,915 $454,000
Q1 2022

May 12, 2022

BUY
$9.74 - $17.69 $132,688 - $240,990
13,623 Added 58.49%
36,915 $454,000
Q4 2021

Jun 21, 2023

SELL
$16.88 - $23.31 $218,714 - $302,027
-12,957 Reduced 35.74%
23,292 $403,000
Q3 2021

Jun 21, 2023

SELL
$16.82 - $25.75 $217,936 - $333,642
-12,957 Reduced 35.74%
23,292 $418,000
Q2 2021

Jun 21, 2023

SELL
$10.16 - $28.86 $131,643 - $373,939
-12,957 Reduced 35.74%
23,292 $532,000
Q1 2021

May 17, 2024

SELL
$5.17 - $16.13 $25,715 - $80,230
-4,974 Reduced 17.6%
23,292 $348,000
Q1 2021

Jun 26, 2023

SELL
$5.17 - $16.13 $66,987 - $208,996
-12,957 Reduced 35.74%
23,292 $348 Million
Q1 2021

Mar 22, 2023

BUY
$5.17 - $16.13 $78,542 - $245,046
15,192 Added 187.56%
23,292 $348,000
Q1 2021

May 14, 2021

BUY
$5.17 - $16.13 $78,542 - $245,046
15,192 Added 187.56%
23,292 $348,000
Q4 2020

May 24, 2024

BUY
$4.01 - $7.58 $13,557 - $25,627
3,381 Added 71.65%
8,100 $43,000
Q4 2020

Jun 22, 2023

SELL
$4.01 - $7.58 $112,877 - $213,369
-28,149 Reduced 77.65%
8,100 $43,000
Q4 2020

Mar 22, 2023

BUY
$4.01 - $7.58 $13,557 - $25,627
3,381 Added 71.65%
8,100 $43,000
Q4 2020

Feb 16, 2021

BUY
$4.01 - $7.58 $13,557 - $25,627
3,381 Added 71.65%
8,100 $44,000
Q3 2020

May 24, 2024

SELL
$3.8 - $5.0 $79,940 - $105,185
-21,037 Reduced 81.68%
4,719 $21.5 Million
Q3 2020

Jun 26, 2023

SELL
$3.8 - $5.0 $119,814 - $157,650
-31,530 Reduced 86.98%
4,719 $21,000
Q3 2020

Mar 22, 2023

SELL
$3.8 - $5.0 $79,940 - $105,185
-21,037 Reduced 81.68%
4,719 $21,000
Q3 2020

Nov 13, 2020

SELL
$3.8 - $5.0 $79,940 - $105,185
-21,037 Reduced 81.68%
4,719 $21,000
Q2 2020

May 24, 2024

SELL
$2.62 - $5.2 $6,576 - $13,052
-2,510 Reduced 8.88%
25,756 $127 Million
Q2 2020

Jun 26, 2023

SELL
$2.62 - $5.2 $27,491 - $54,563
-10,493 Reduced 28.95%
25,756 $126,000
Q2 2020

Mar 22, 2023

SELL
$2.62 - $5.2 $27,491 - $54,563
-10,493 Reduced 28.95%
25,756 $126,000
Q2 2020

Aug 14, 2020

BUY
$2.62 - $5.2 $67,480 - $133,931
25,756 New
25,756 $127,000

Others Institutions Holding AVXL

About ANAVEX LIFE SCIENCES CORP.


  • Ticker AVXL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,942,800
  • Market Cap $352M
  • Description
  • Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...
More about AVXL
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.